Published in Medicine and Law Weekly, December 16th, 2005
This compares to revenues of $1.1 million and a net loss of $4.2 million, or $0.08 per share, for the same period last year. Cash used to fund operations for the first 3 months was $8.9 million as compared to $5.0 million for the same period last year. The increased use of cash of $3.9 million is due primarily to the ALLEVIATE trials evaluating epratuzumab in patients with lupus, and lower sales revenue from diagnostic imaging products.
At September 30, 2005, the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.